IBA Business Update – Third Quarter 2022

-

Thursday, November 17, 2022 - 8:43

<p><span><span><span><span><span><strong><span lang="EN-US"><span>Louvain-La-Neuve, Belgium, 17 November 2022 </span></span></strong><span lang="EN-US"><span>- IBA (Ion Beam Applications S.A., </span></span><span lang="EN-US"><span>EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022.</span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><strong><span><span><span><span><span><span lang="EN-GB"><span>Group Overview</span></span></span></span></span></span></span></strong></p> <ul> <li><span><span><span><span><span lang="EN-GB"><span>Business operations continue to be strong, with good performance across all four business units </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million) </span></span></span></span></span></span></li> </ul> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-US"><span>Olivier Legrain, Chief Executive Officer of IBA commented:</span></span></strong><strong><span lang="EN-US"><span> </span></span></strong><span lang="EN-US"><span>“IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.” </span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-GB"><span>Proton Therapy </span></span></strong></span></span></span></span></span></p> <ul> <li><span><span><span><span><span lang="EN-GB"><span>24 projects ongoing in Proton Therapy, with nine Proteus<sup>®</sup>PLUS<sup>1</sup> and 15 Proteus<sup>®</sup>ONE<sup>1</sup> systems in progress </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>An active global pipeline, highlighting the strength of proton therapy market across all geographies </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>A total of 40 service contracts now generating recurring revenues globally</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH<sup>®2</sup> Proton Therapy</span></span></span></span></span></span></li> <li><span><span><span lang="EN-GB"><span>Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL)</span></span></span></span></li> </ul> <p><span lang="EN-US"><span><span>The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer</span></span></span></p> <div> <p><span><span><span><span><span><strong><span lang="EN-GB"><span>Other Accelerators (RadioPharma, Industrial)</span></span></strong></span></span></span></span></span></p> <ul> <li><span><span><span><span><span lang="EN-GB"><span>Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone<sup>®</sup> IKON in Chengdu, Sichuan Province, China</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron<sup>®</sup> electron beam accelerators for commercial production of radioisotopes</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Launched </span></span><span lang="EN-GB"><span>Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab<sup>®</sup> PLUS in Ghana</span></span></span></span></span></span></li> </ul> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-GB"><span>Dosimetry</span></span></strong></span></span></span></span></span></p> <ul> <li><span><span><span><span><span lang="EN-GB"><span>Signed a strategic alliance for radiation therapy dosimetry solutions with ScandiDos A.B. (SDOS.ST) and made a minority investment in the company </span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>IBA’s dosimetry solutions were made compatible with Halcyon<sup>®</sup> and Ethos™ radiotherapy and adaptive therapy solutions</span></span><span lang="EN-GB"><span>, post-period end</span></span></span></span></span></span></li> <li><span><span><span><span><span lang="EN-GB"><span>Expanded IBA’s myQA</span></span><sup><span lang="EN-GB"><span>®</span></span></sup><span lang="EN-GB"><span> iON technology into Radiation Therapy</span></span><span lang="EN-GB"><span>, post-period end</span></span></span></span></span></span></li> </ul> <p>&nbsp;</p> <p><strong><span><span><span><span><span><span lang="EN-GB"><span>Outlook </span></span></span></span></span></span></span></strong></p> <p><span><span><span><span><span><span lang="EN-GB"><span>IBA has continued to perform well across all business units in 2022 to date and this momentum is expected to persist for the remainder of the year and beyond. The pipeline remains highly active in all businesses, underpinning visibility for the period ahead. Whilst some supply chain and inflation related challenges remain, we are seeing gradual improvements and as a business, we continue to mitigate macroeconomic pressures. With an exceptionally strong balance sheet, we are continuing with our extensive investment plan to bolster our infrastructure, supply chain and logistics, reinforce our digital ambitions and continue to maintain our market-leading technology. Alongside this, we will look to </span></span><span lang="EN-US"><span>seek value-enhancing opportunities to drive future sustainable growth. </span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><strong><span><span><span><span><span><span lang="EN-GB"><span>Financial calendar </span></span></span></span></span></span></span></strong></p> <p><span><span><span><span><span><span lang="EN-US"><span>Full Year Results 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23 March 2023</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span lang="EN-US"><span>Business Update First Quarter 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18 May 2023</span></span></span></span></span></span></span></p> <p><span lang="EN-US"><span>General Assembly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 June 2023</span></span></p> <p>&nbsp;</p> <p>&nbsp;</p> <ol> <li><em><span lang="EN-US"><span><span>Proteus<sup>®</sup>PLUS and Proteus<sup>®</sup>ONE are brand names of Proteus 235</span></span></span></em></li> <li><em><span lang="EN-US"><span><span>ConformalFLASH<sup>®</sup> is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.</span></span></span></em></li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> </div> Read full press release EN  
Read full press release FR  
Share

More news

-

IBA Reports Full Year 2022 Results

ALL-TIME RECORD ORDER INTAKE AND BACKLOG IBA ANNOUNCES MID-TERM GUIDANCE Louvain-la-Neuve, Belgium, 23 March 2023 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2022 financial year.&nbsp; &nbsp; Financial summary All-time record annual Equipment order intake of EUR 456 million and Dosimetry order intake of EUR 67 million All-time record overall Equipment and Services backlog of EUR 1.4 billion including Equipment backlog of EUR 713 million an Services backlog of EUR 669 million Total 2022 Group revenues up 15% from 2021 to EUR 361.3 million&nbsp; Proton Therapy and Other Accelerators Services revenue increased 12.8% versus last year to EUR 135 million Gross margin was 35.1%, compared to 34.4% in 2021 Positive 2022 REBIT of EUR 11.1 million, down from EUR 14.5 million in 2021, due to the high inflationary environment, as well as increased investment into R&amp;D, infrastructure, digital technologies and sustainability to maintain IBA’s leading offering and invest in its future growth Total Group net profit of EUR 6.1 million (2021: EUR 3.9 million), positively impacted by deferred tax assets recognition related to improvement of future profitability Strong balance sheet with EUR 158 million gross and EUR 117 million net cash&nbsp; Mid-term guidance announced and dividend of EUR 0.21 per share proposed by the Board, a 10% increase from last year&nbsp; &nbsp; Business summary&nbsp; 17 new proton therapy rooms sold in 2022, compared to nine last year Other Accelerators order intake of 36 systems compared to 31 in 2021 Dosimetry order intake up 22% to a record EUR 67 million Three new installations in PT and 32 installations in Other Accelerators started during the year with four completed in PT and 20 in Other Accelerators Good progress across IBA’s four strategic sustainability streams: a) low carbon, low waste products b) low carbon, low waste company c) diverse equitable and inclusive workplace and d) accountability towards sustainability&nbsp; Olivier Legrain, Chief Executive Officer of IBA, commented: “Despite the headwinds from the global macro-economic environment, IBA has seen another strong year, driven by increasing sales across all of its business units and an all-time record order intake and backlog. On the Proton Therapy side, we have seen significant traction in Europe and the US in 2022. In addition, I’m pleased with the continued pace of deals within Industrial Solutions especially, which has continued into the start of 2023. During the year we have also been focused on future-proofing the business with targeted investments to support the Group in executing on its record backlog as well as maintaining our leading market position. With our strong backlog, good revenue visibility and high cash position, we are confident on IBA’s positive outlook for 2023 and beyond.”&nbsp; &nbsp;
See more

Is PET the future of nuclear cardiology- why?

Cardiovascular diseases are the leading cause of death in the United States and worldwide. In the light of the changing landscape of cardiac diseases epidemiology, conventional imaging techniques are no longer effective for diagnosis, risk assessment, and patient management . In contrast, quantitative PET provides absolute measurements that can help tackle these challenges and significantly improve patient care.&nbsp; &nbsp; In this webinar, Dr Di Carli from Brigham and Women's Hospital and Dr. Buechel from University Hospital Zurich will explain why they believe PET imaging is the future in management of CVD.
See more
-

Newsletter 29 is out!

PanTera, IBA Users Meetings, FAPI on Synthera, riggings, site acceptance test,…read it all in our autumn Newsletter !
See more
-

Rigging of the Cyclone® KIUBE at Neijang

The cyclotron was rigged into HIC’s vault at Neijang in China. The new radiopharmacy will soon be able to produce F-18 compounds. &nbsp; Congratulations to all the people involved in this project!
See more